NCT02484443: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma |
|
|
| Completed | 2 | 41 | Canada, US, RoW | Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin | National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma | 03/20 | 09/23 | | |
DiTuSarc, NCT05080790: Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma |
|
|
| Recruiting | 2 | 10 | Europe | Dinutuximab Beta, Zoledronic acid, Interleukin-2 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, EUSA Pharma, Inc. | Leiomyosarcoma | 07/24 | 07/24 | | |
